ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $20.851 million which beat the analyst consensus estimate of $19.240 million by 8.37 percent. This is a 9.46 percent decrease over sales of $23.030 million the same period last year.